Back to Search
Start Over
Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy.
- Source :
- Oncologist; Oct2024, Vol. 29 Issue 10, p842-849, 8p
- Publication Year :
- 2024
-
Abstract
- Introduction Early discontinuation of endocrine therapy (ET) is higher among patients with early breast cancer (EBC) compared to patients with metastatic hormone receptor-positive (HR+) breast cancer (MBC). In our clinical experience the reasons for this may include a significant burden of ET side effects impacting quality of life (QOL) in patients with EBC. We hypothesized that QOL is lower in patients with HR + EBC compared to patients with HR + MBC on ET. Methods We conducted a cross-sectional observational study to assess QOL utilizing FACT-ES & EORTC QLQ C30 tools among patients with EBC and MBC receiving ET across 5 Irish hospitals. Results A total of 417 patients were enrolled—EBC (79% n = 331) and MBC 21% (n = 86). Using the FACT-ES, we found no difference in overall QOL by stage (139.2 vs 141, P = .33). Patients with HR + MBC had a lower symptom burden from ET compared to HR + EBC (61.4 vs 54, P < .01). In adjusted multivariate linear regression models, there was no difference in QOL for patients with EBC and MBC receiving ET. Conclusions There was no significant difference in overall QOL for patients with EBC and MBC. However, patients with EBC experienced more endocrine symptoms. In adjusted multivariate linear regression models, the stage did not predict QOL. Our results suggest that endocrine symptoms are significant contributors to impaired QOL for patients with EBC but the role of other determinants of QOL (eg, stage) is less clear. Future work could include the development of stage-specific QOL tools and utilization of electronic patient-reported outcomes (ePROs) to identify and manage emergent toxicities. [ABSTRACT FROM AUTHOR]
- Subjects :
- CROSS-sectional method
HORMONE receptor positive breast cancer
PREDICTION models
RESEARCH funding
BREAST tumors
SCIENTIFIC observation
MULTIPLE regression analysis
FISHER exact test
MULTIVARIATE analysis
CHI-squared test
DESCRIPTIVE statistics
QUALITY of life
ONCOGENES
ENDOCRINE diseases
HEALTH outcome assessment
DATA analysis software
NONPARAMETRIC statistics
Subjects
Details
- Language :
- English
- ISSN :
- 10837159
- Volume :
- 29
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 180152668
- Full Text :
- https://doi.org/10.1093/oncolo/oyae146